To determine whether the balance of AMPD2 and AMPK can be altered in this model to block the development of fatty liver, surviving rats were randomized to receive metformin (350 mg/kg/d) or vehicle for 4 additional weeks. The gene discussed is AMPD2; the disease is Hepatic steatosis.